Bias found in mental health drug research presented at major psychiatric meeting

May 22, 2012

When thousands of psychiatrists attend their field's largest annual meeting each year, the presentations they hear about research into drug treatments report overwhelmingly on positive results.

That's the finding of a new study published in the Journal of Clinical Psychopharmacology by two young psychiatrists from the University of Michigan and Yale University, who analyzed the presentations given at two recent meetings of the .

Of 278 studies presented at the 2009 and 2010 APA meetings that compared at least two medicines against each other for any , they found that 195 had been supported by industry, and 83 funded by other means. The authors then evaluated the studies without knowing which kind of support each one had.

Of the industry-supported studies, 97.4 percent reported results that were positive toward the medicine that the study was designed to test, and 2.6 percent reported mixed results. No industry-sponsored studies with negative results were found.

In contrast, when industry was not the source of funding, 68.7 percent of the presentations were positive, and 24.1 percent contained mixed results, while 7.2 percent contained negative results.

This 'presentation bias', in which mostly good news about medicines gets reported at meetings, the 'publication bias' that has been seen in research published in major journals, says Srijan Sen, M.D., Ph.D., an assistant professor of psychiatry at the U-M Medical School who led the study while in his residency at Yale.

While attending the APA's massive annual meeting, he noted the large industry presence and emphasis on research involving medicines that were still "on patent" and being actively marketed to both psychiatrists attending the conference. He teamed with Yale psychiatry resident Maya Prabhu, M.D., M.Sc., now a consulting forensic psychiatrist at Yale, to do a formal review.

"This analysis suggests that the APA meeting might be being used as an opportunity to make drugs seem more effective than they are," he says.

Meanwhile, research on "talk therapy" treatments such as cognitive behavioral therapy – which doesn't have industry backing – gets less attention, even though there is growing evidence that such non-drug therapies can have as much effect as medicines in illnesses such as depression.

Since the APA meeting is a major source of continuing medical education credit for psychiatrists, and a hub for psychiatry residents just starting out in the field, the bias has the potential to affect their clinical care when they return home.

Sen notes that the research journals and funding agencies have tried to confront research bias in journal articles by requiring pharmaceutical companies to register the clinical trials they are conducting and include the registration number when publishing the study. This allows interested individuals to see which trials are being reported in the medical literature, and whether the trial results are interpreted according to the original study design.

For instance, if a drug trial is designed to test long-term results from a particular treatment, but a paper is published showing positive over a much shorter term, that could be an indication of bias. Research meetings could require a similar practice, Sen says. And, APA could be more selective in accepting poster presentation submissions.

If nothing else, Sen says, attendees at the APA's meeting – and perhaps other large gatherings of psychiatrists – should be aware of the positive bias of the research they will hear about at the meeting.

And, non-industry funding for research – especially research to compare older "off patent" drugs that aren't being marketed by industry – is also important, he says. The federal government has funded large comparison studies in depression, schizophrenia and bipolar disorder, he notes – and these mostly showed that the generic medications that have lost their patent protection are just as effective as newer, patent-protected ones. But even still, prescribe the generic ones far less often than the brand-name patent-protected ones.

Explore further: Publication bias involving psychiatric medications may provide physicians with an incomplete picture

More information: Journal of Clinical Psychopharmacology, Volume 32, Number 3, June 2012.

Related Stories

Publication bias involving psychiatric medications may provide physicians with an incomplete picture

March 20, 2012
Physicians who prescribe antipsychotic medications may be basing their decisions on incomplete information, according to new research published by scientists at Oregon Health & Science University. The study is published in ...

Recommended for you

Researchers crack the smile, describing three types by muscle movement

July 27, 2017
The smile may be the most common and flexible expression, used to reveal some emotions, cover others and manage social interactions that have kept communities secure and organized for millennia.

Even babies can tell who's the boss, UW research says

July 27, 2017
The charismatic colleague, the natural leader, the life of the party - all are personal qualities that adults recognize instinctively. These socially dominant types, according to repeated studies, also tend to accomplish ...

Infants know what we like best, study finds

July 27, 2017
Behind the chubby cheeks and bright eyes of babies as young as 8 months lies the smoothly whirring mind of a social statistician, logging our every move and making odds on what a person is most likely to do next, suggests ...

DREAMers at greater risk for mental health distress

July 27, 2017
Immigrants who came to the United States illegally as small children and who meet the requirements of the Development Relief and Education for Alien Minors Act, more commonly known as DREAMers, are at risk for mental health ...

Ketamine for depression encouraging, but questions remain around long-term use

July 27, 2017
A world-first systematic review into the safety of ketamine as a treatment for depression, published in the prestigious Lancet Psychiatry, shows the risks of long-term ketamine treatment remain unclear.

Negativity, be gone—new online tool can retrain your brain

July 27, 2017
Anxiety and depression can have devastating effects on people's lives. In some cases, the mental disorders lead to isolation, poverty and poor physical health, things that often cascade to future generations.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.